Copertina

The safety of semaglutide in patients with depression and obesity

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ziyi Yang, Yimin Yan
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Obesity
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Response to “The safety of semaglutide in patients with depression and obesity”
di: Robert F. Kushner, et al.
Pubblicazione: (2024)

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity
di: Aurélie Phan, et al.
Pubblicazione: (2025)

Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
di: Alberte Laura Oest Müllertz, et al.
Pubblicazione: (2024)

Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
di: Manish R. Bhise, et al.
Pubblicazione: (2025)

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
di: Jason M. Samuels, et al.
Pubblicazione: (2025)

Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
di: Hendra Zufry, et al.
Pubblicazione: (2025)

Investigating shared genetic architecture between major depressive disorder and central obesity
di: Ya Zhan, et al.
Pubblicazione: (2025)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
di: Erik Stenberg, et al.
Pubblicazione: (2024)

Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system
di: Ning Wang, et al.
Pubblicazione: (2026)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
di: Alpana P. Shukla, et al.
Pubblicazione: (2025)

Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence
di: Alexandra A. Weinreich, et al.
Pubblicazione: (2025)

Titration and discontinuation of semaglutide for weight management in commercially insured US adults
di: Yunwen Xu, et al.
Pubblicazione: (2025)

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
di: Maria Buur Nordskov Gabe, et al.
Pubblicazione: (2024)

Unraveling the obesity paradox in polytrauma patients: survival benefit specifically in individuals with obesity class I
di: Hui‐Tzung Luh, et al.
Pubblicazione: (2025)

Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
di: Chenyang Shi, et al.
Pubblicazione: (2024)

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
di: Emily R. Hankosky, et al.
Pubblicazione: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
di: Flora Lambert, et al.
Pubblicazione: (2025)

The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus—A pilot study
di: Petra Melis, et al.
Pubblicazione: (2025)

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study
di: Jamy D. Ard, et al.
Pubblicazione: (2025)

Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study
di: Silvana Costa, et al.
Pubblicazione: (2025)

A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
di: Panpan Xie, et al.
Pubblicazione: (2024)

Sex differences in perceived discrimination among patients with obesity
di: Marianne O. Olaniran, et al.
Pubblicazione: (2024)

Myocardial mechano‐energetic efficiency is not impaired in patients with metabolically healthy overweight and obesity
di: Chiara Maria Assunta Cefalo, et al.
Pubblicazione: (2024)

Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
di: Dario Giugliano, et al.
Pubblicazione: (2024)

Comparative safety of glucose‐lowering medications on depression in adults with type 2 diabetes
di: Stephanie A. Hooker, et al.
Pubblicazione: (2026)

Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
di: Meredith M. Hoog, et al.
Pubblicazione: (2025)

Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
di: Weijun Gu, et al.
Pubblicazione: (2025)

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
di: Domenica Rubino, et al.
Pubblicazione: (2024)

Medical semiology of patients with monogenic obesity: A systematic review
di: Emeline Renard, et al.
Pubblicazione: (2024)

Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
di: Beverly G. Tchang, et al.
Pubblicazione: (2025)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
di: Stergios A. Polyzos, et al.
Pubblicazione: (2026)

Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
di: Jean‐François Yale, et al.
Pubblicazione: (2024)

BMI and mortality in critically ill patients with COVID‐19: another brick in the wall of the obesity paradox
di: Amanda Vilaverde Perez, et al.
Pubblicazione: (2024)

Lifestyle behavioral weight‐loss treatment for binge‐eating disorder in patients with obesity: where's the harm?
di: Sydney Yurkow, et al.
Pubblicazione: (2025)

Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweight
di: Donald M. Bushnell, et al.
Pubblicazione: (2025)

Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy
di: Firas Bahdi, et al.
Pubblicazione: (2025)

Gap of women leadership in global obesity research
di: Xiangxin Kong, et al.
Pubblicazione: (2025)

Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
di: Yingying Xiang, et al.
Pubblicazione: (2024)

Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
di: Takefumi Kishimori, et al.
Pubblicazione: (2026)

Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
di: Kevin Cowart, et al.
Pubblicazione: (2025)